Who should be screened for diabetes now?
SGLT2 Inhibitor Lowers Blood Pressure Across Medication Classes
In patients taking SGLT2 inhibitors who had treated hypertension, a new study compared the drop in blood pressure seen with a diuretic to declines seen with other classes of antihypertensive medications.
SGLT2 Inhibitor Reduces Visceral Adiposity in T2DM
The mechanism underlying the ability of empagliflozin to reduce measures of visceral adiposity may be a redistribution of fat to less vulnerable body areas.
Top Diabetes Article of 2014: Your Vote?
In the blizzard of articles about diabetes that deluged your desk in 2014, were there one or two that struck you as particularly noteworthy? Cast your vote!
Polypharmacy Perils: What's Wrong with this Rx Plan?
The patient is new to you, he's got type 2 DM and has a lot of meds on board. There's danger in this mix. Read the history and see if you spot the problem.
Some Patients Still Make it Worthwhile
This is a short list of the little things that eat away at my energy and goodwill. Thank goodness there are still patients who make it worthwhile.
Less Severe Diabetes Has Better Remission With Surgery
After sleeve gastrectomy, obese patients with type 2 DM who have less severe disease do better than those who have more advanced disease. Surgery should be encouraged sooner rather than later.
Cost of Care Lower with SGLT2 Inhibitor vs DPP-4 Inhibitor
Some of the reasons cited for the observed cost efficiencies: better achievement of A1C and composite quality-of-care goals and fewer treatment failures.
By clicking Accept, you agree to become a member of the UBM Medica Community.